Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vaccinium arctostaphylos extract is a botanical extract derived from the fruit or leaves of the Caucasian whortleberry (*Vaccinium arctostaphylos* L.), a member of the Ericaceae family native to regions like Iran and the Caucasus. Rich in anthocyanins (such as delphinidin, cyanidin, and malvidin glycosides) and phenolic compounds like chlorogenic acid and quercetin, the extract has been investigated for its potential therapeutic effects in metabolic and cardiovascular disorders. Clinical studies suggest it may possess anti-hyperglycemic, anti-dyslipidemic, and anti-hypertensive properties, potentially through the inhibition of alpha-glucosidase and modulation of oxidative stress and inflammatory markers. Additionally, experimental models have explored its neuroprotective role in conditions like glaucoma, where it appears to enhance mitochondrial enzyme activity and reduce lipid peroxidation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on vaccinium arctostaphylos extract.